Tricuspid Intervention in Heart Failure (TRICI-HF-DZHK24)

An insufficient tricuspid valve is a severe and progressive disease that often leads to a progressive deterioration of the clinical condition. Until some time ago, only cardiac surgery was available to treat the valve. Only during the last few years have minimally invasive treatment methods using cardiac catheter technology become available.

The DZHK study TRICI-HF-DZHK24 is the first industry-independent, multi-centre study to examine for several such catheter-based systems whether this intervention brings benefits to patients compared to a purely drug-based therapy. For this purpose, the scientists assess how many patients survive over 12 months after the intervention and whether hospitalisation due to heart failure becomes necessary.

TRICI-HF-DZHK24 - Tricuspid Intervention in Heart Failure (TRICI-HF-DZHK24)

Publications

There are no publications aivailable yet.

Principal Investigators

Principal investigator: Jörg Hausleiter (München), Co-PI: Thomas Stocker, Daniel Braun, Steffen Massberg (München)

Press releases and news

16.02.2022
 

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.

Study information
TRICI-HF-DZHK24

Recruiting status
Recruiting ongoing
Recruitment start
03.2022
Patients
265
360
Clinical Trials Registrierung

NCT04634266

Category
Guideline relevant study
DZHK Funding
€ 1.767.774
Links
https://tric-i-hf.dzhk.de/

Operative contact
Main study center
PD Dr. med. Thomas J. Stocker
thomas.stocker@med.uni-muenchen.de

Studienzentren/Kontakt (PDF)